Cystic Fibrosis News

SAN DIEGO — In a cohort of nearly 300 pediatric patients with cystic fibrosis, food allergy was found in less than 4% of the population, which was a lower proportion than the general pediatric population, according to a presentation here.

The FDA granted orphan drug designation to porosome reconstitution therapy for treating patients with cystic fibrosis, according to a press release from Porosome Therapeutics.

Having a child with vs. without cystic fibrosis heightened the odds for job lock and curtailed employment among parents/caregivers, according to a research letter published in JAMA Pediatrics.

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally tolerated it well, according to data published in The Lancet Respiratory Medicine.

Among individuals aged at least 12 years with cystic fibrosis, receipt of vanzacaftor/tezacaftor/deutivacaftor was similar or better than Trikafta depending on the endpoint, according to results published in The Lancet Respiratory Medicine.

At three follow-up visits within 6 months, reports of neuropsychological side effects rose or stayed stable among patients with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor therapy, according to results published in CHEST.

The FDA has approved Alyftrek for patients aged 6 years and older with cystic fibrosis with certain mutations, according to a press release from Vertex Pharmaceuticals.

Among patients with advanced cystic fibrosis lung disease, two cardiopulmonary exercise testing outcomes could predict death/lung transplantation, according to results published in Annals of the American Thoracic Society.

Percent-predicted FEV1 and respiratory-related quality of life improved with 28-day triple therapy in individuals with the N1303K cystic fibrosis transmembrane conductance defect, according to data published in Lancet Respiratory Medicine.